FDA Approves First Nasal Spray for Anaphylaxis

• 21 Aug 2024

In August 2024, the United States FDA has approved Neffy, the first-ever nasal spray designed for the emergency treatment of severe allergic reactions, offering a painless alternative to epinephrine injections.

Key Points

• FDA Approval of Neffy: The FDA has approved Neffy, the first nasal spray for treating severe allergic reactions, offering a painless alternative to epinephrine injections.
• Convenience for Patients: Neffy provides a simple and effective way to treat life-threatening allergic reactions without the need for injections.
• Importance of Epinephrine: Epinephrine remains the only life-saving treatment for anaphylaxis, relaxing airway muscles and constricting blood vessels.
• Impact on Low-Income Countries: The nasal spray is particularly significant for countries where auto-injectors are scarce, simplifying the treatment process.
• Benefits for Children: Neffy is especially beneficial for children who fear injections and need an easy-to-use alternative.
• Common Allergens Identified: The most common allergens include foods, medications, and insect venom, with varying impacts on children and adults.